Loading...
Powered By
16 items
2025-07-21
On July 17, 2025, Mason Capital Corporation closed the transaction.
2025-07-15
Medical Net, Inc., 2025 Earnings Call, Jul 30, 2025
2025-06-30
Medical Net, Inc. announced a private placement to issue 538,600 ordinary shares at an issue price of ¥288 for gross proceeds of ¥155,116,800 on June 26, 2025. The transaction includes participation from new investor, Yoshida Co., Ltd. and will held 5.81% stake in the company. The transaction will happen through third party allocation. The issue date will be July 18, 2025. The transaction has been approved at board of director meeting of the company. The company will bear issuance expenses of ¥1,300,000 and will receive net proceeds of ¥153,816,800.
2025-05-24
Medical Net, Inc. announced that they will report fiscal year 2025 results on Jul 15, 2025
2025-04-07
The company closed its plan on April 7, 2025.
2025-04-07
From October 28, 2024 to April 7, 2025, the company has repurchased 313,400 shares, representing 3.46% for ¥99.98 million. With this, the company has completed the repurchase of 313,400 shares, representing 3.46% for ¥99.98 million under the buyback announced on October 28, 2024.
2025-02-26
Medical Net, Inc. announced that they will report Q3, 2025 results on Apr 14, 2025
2025-01-15
Medical Net, Inc., ¥ 3.00, Cash Dividend, May-29-2025
2025-01-14
Medical Net, Inc. expected to report Q3 2025 results on April 11, 2025. This event was calculated by S&P Global (Created on January 14, 2025).
2025-01-08
Medical Net, Inc., Q2 2025 Earnings Call, Jan 23, 2025
2024-11-23
Medical Net, Inc. announced that they will report Q2, 2025 results on Jan 14, 2025
2024-10-28
Medical Net, Inc. (TSE:3645) announces a share repurchase program. Under the program, the company will repurchase up to 400,000 shares, representing 4.42% of its share capital for ¥100 million. The purpose of program is to improve shareholder profits through improved capital efficiency and to enable the implementation of a flexible capital policy in response to changes in the environment. As of August 31, 2024, the company had 9,045,270 shares outstanding (excluding treasury shares) and 1,727,730 shares in treasury.
2024-10-28
The Board of Directors of Medical Net, Inc. has authorized a buyback plan on October 28, 2024.
2024-09-03
Medical Net, Inc. expected to report First-Half, 2025 results on January 10, 2025. This event was calculated by S&P Global (Created on September 3, 2024).
2024-08-30
MiRTeL Co., Ltd announced that it will issue 352,942 common shares at an issue price of ¥170 per share for the gross proceeds of ¥60,000,140 on August 29, 2024. The transaction will include participation from returning investor Medical Net, Inc. The transaction is expected to close on September 18, 2024. The company will issue common shares through third-party allotment.
2024-08-24
Medical Net, Inc. announced that they will report Q1, 2025 results on Oct 15, 2024
2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 | 2024Q2 | 2024Q1 | 2023Q4 | 2023Q3 | |
|---|---|---|---|---|---|---|---|---|
Total Revenues | 6,077 | 6,018 | 5,822 | 5,511 | 5,252 | 5,030 | 4,845 | 4,628 |
Pretax Income Excl.Unusual Items | 134 | 160 | 195 | 274 | 321 | 397 | 404 | 372 |
Total Assets | 4,080 | 4,131 | 4,354 | 3,886 | 3,989 | 3,669 | 3,568 | 3,375 |
Total Liabilities | 2,313 | 2,424 | 2,465 | 2,014 | 2,059 | 1,704 | 1,541 | 1,446 |
Cash & Cash Equivalents | 1,456 | 1,401 | 1,443 | 1,367 | 1,528 | 1,438 | 1,399 | 1,453 |
Total Common Equity | 1,715 | 1,656 | 1,848 | 1,841 | 1,906 | 1,943 | 2,011 | 1,917 |
Book Value Per Share (BVPS) | 196.41 | 186.46 | 205.38 | 203.53 | 210.72 | 214.81 | 222.33 | 211.93 |
Net Change in Cash | -104 | 30 | -5 | 226 | ||||
Capital Expenditure | -131 | -39 | -32 | -26 |
Medical Net revealed its financial results for the second quarter of 2025 on July 18, 2025, with revenues of 1.66B yen and net income of 77M yen, representing a revenue increase of 3.7%, with a transition from a loss per share in the same quarter last year to a profit per share in the current quarter. A positive note is that for the 20th consecutive quarter, the company's revenue line has increased compared to last year's corresponding quarter, which demonstrates the company's stability and its ability to grow in the future.
Moreover, the EBITDA margin decreased significantly from 5% to 3.5% in the comparable quarter previous year. A decline in operating profitability can signify a problem with sales or a rise in operating expenses, which could be detrimental to the stock's performance in the future. and it trades at 1.63 times price to book ratio, which is lower than the industry average (P/B 1.82).